



*vaccines*



an Open Access Journal by MDPI

## mRNA Vaccine Development against Tropical Diseases

Guest Editor:

**Dr. Cristina Poveda**

Baylor College of Medicine,  
Houston, TX, USA

Deadline for manuscript  
submissions:

**closed (28 February 2023)**

### Message from the Guest Editor

Dear Colleagues,

Vaccination is the most effective way to prevent infectious diseases. However, complex pathogens such as *Plasmodium* (Malaria), *Trypanosoma cruzi* (Chagas), *Trypanosoma brucei* (African Sleeping Sickness), *Leishmania*, Zika, and others have not been yet effectively tackled with conventional vaccines. mRNA vaccines for COVID-19 demonstrated how plasticity can accelerate the development of new vaccines for complex diseases.

We are pleased to announce this Special Issue on “mRNA Vaccine Development against Tropical Diseases”. The issue centers on (1) screening and identifying suitable vaccine candidates using novel in vitro techniques and assays, which allows for a better understanding of the biological and immunological complexities of pathogens, infection, and disease; (2) progress in nucleic acid delivery technology and how it improves vaccine potency and safety; and (3) the regulatory and manufacturer challenges to implementations in the regions (Asia, Africa, Latin America).

Dr. Cristina Poveda  
*Guest Editor*



[mdpi.com/si/121267](https://mdpi.com/si/121267)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)